Transcriptomic analysis of fibroblast from 10 Ehlers-Danlos SYndrome (EDS) patients.

Ehlers-Danlos SYndrome (SEDSY) was performed compared to 4 control healty samples with the aim to identify dysregulated genes and pathways and to use this information to propose potential drugs that could be repurposed for the treatment, based on computational approaches to drug repositioning.In summary, this comprehensive study expands our understanding of the molecular basis of Ehlers-Danlos syndrome, particularly relating to COL3A1 mutations. The integration of transcriptomic analysis, pathway studies, and drug repurposing strategies provides a robust framework for identifying potential therapeutic strategies for EDS. Overall design: Total RNA was extracted from 10 Ehlers-Danlos SYndrome (EDS) patients and 4 controls